Status:
COMPLETED
ChAdOx1 85A Aerosol Versus Intramuscular Vaccination in Healthy Adults (TB039)
Lead Sponsor:
François Spertini
Collaborating Sponsors:
University of Oxford
Conditions:
Mycobacterium Tuberculosis, Protection Against
Tuberculosis
Eligibility:
All Genders
18-55 years
Phase:
EARLY_PHASE1
Brief Summary
This is a dose escalating and a paired-placebo design study to describe the safety and immunogenicity profile of candidate TB vaccine ChAdOx1 85A given by aerosol inhaled vaccination versus intramuscu...
Detailed Description
Background: Mycobacterium tuberculosis (M.tb) is a pathogen with worldwide preponderance which infects humans and causes tuberculosis (TB), a transmissible disease resulting in very high mortality an...
Eligibility Criteria
Inclusion
- Healthy adult aged 18-55 years.
- Give informed consent as documented by signature.
- Screening Interferon-Gamma release assay (IGRA) negative.
- Chest radiograph normal.
- Prior vaccination with BCG (except Group F).
- No relevant findings in medical history or on physical examination.
- Allow the Investigators to discuss the individual's medical history with their GP, if appropriate.
- Use effective double contraception for the duration of the trial period (females and males).
- Refrain from blood donation during the trial.
- Able and willing (in the Investigator's opinion) to comply with all the trial requirements.
Exclusion
- Previously resident for more than 12 consecutive months in a highly endemic area (tropical) where significant TB and non-tuberculous mycobacterial exposure is likely.
- Participation in another research trial involving receipt of an investigational product in the 30 days preceding enrolment, or planned use during the trial period.
- Participation in a clinical trial involving vaccination with an adenovirus vector (such as Ebola or HIV trials)
- Prior vaccination with any candidate TB vaccine.
- Vaccination with any live, attenuated vaccine within 28 days prior to enrolment.
- Vaccination with any subunit or killed vaccine within 14 days prior to enrolment (influenza vaccination is encouraged prior to participation).
- Prior vaccination with BCG (Group F only).
- Administration of immunoglobulins and/or any blood products within the three months preceding the enrolment.
- Clinically significant history of skin disorder, allergy, atopy, immunodeficiency (including HIV), cancer (except basal cell carcinoma or carcinoma in situ), cardiovascular disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder, neurological illness, psychiatric disorder, drug or alcohol abuse.
- Concurrent oral or systemic steroid medication or the concurrent use of other immunosuppressive agents.
- History of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the trial agent, sedative drugs, or any local or general anaesthetic agents.
- Pregnancy, lactation or intention to become pregnant during trial period.
- Any respiratory disease, including perennial asthma, non-controlled seasonal allergic asthma
- Smoking more than 3 cigarettes/day.
- Clinically significant abnormality on screening chest radiograph.
- Clinically significant abnormality of spirometry.
- Any nasal, pharyngeal, or laryngeal finding which precludes bronchoscopy.
- Current use of any medication taken through the inhaled route.
- Clinical, radiological, or laboratory evidence of current active TB disease.
- Past treatment for TB disease.
- Any clinically significant abnormality of screening blood or urine tests.
- Positive HBsAg, HCV or HIV antibodies.
- Any other significant disease, disorder, or finding, which, in the opinion of the Investigator, may either put the volunteer at risk, affect the volunteer's ability to participate in the trial or impair interpretation of the trial data.
Key Trial Info
Start Date :
January 22 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 24 2020
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT04121494
Start Date
January 22 2019
End Date
August 24 2020
Last Update
September 25 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre hospitalier universitaire vaudois
Lausanne, Switzerland, 1011